Biolevate

Biolevate ARR hit 20x growth in a year following €30M Series A funding

Biolevate has achieved impressive commercial traction, increasing ARR by 20x within the last twelve months. The company's hyperspecialised AI platform accelerates regulatory and operational workflows for enterprise life sciences customers, offering efficiency gains as high as 16x in systematic literature reviews and 80% in regulatory intelligence. With more than a dozen enterprise customers using the platform, Biolevate has scaled its operations, doubled headcount to 50 employees, and plans to increase this further by 100%. Fueled by its €30 million Series A funding round co-led by RAISE France and Orange Ventures, the company aims to strengthen international expansion, deepen product capabilities, and solidify its position as a leader in evidence-grade AI automation for healthcare.